Table 1. Literature review.

Literature review of patients with midline hypothalamic/supra-sellar low-grade glioma treated with BRAF inhibitors

b/l, bilateral

Reference	Age/sex	Tumor location	Genomic findings	Chemotherapy	Targeted therapy	Response	Targeted therapy toxicities
Lassaletta et al. [10]	2 months/male	Hypothalamic/chiasmatic	BRAF-V600E	Vinblastine x 1 week	Dabrafenib	Profound/sustained radiological response	Moderate eczema
						Improvement in vision/weight gain
						Normalization of neurodevelopment
Wagner et al. [11]	3 months/male	Hypothalamic/chiasmatic	BRAF: KIAA1549 fusion	Vincristine/carboplatin x 12 weeks	Trametinib	Profound/ sustained radiological response	Nil
						Improvement in vision/weight gain
				Vinblastine x 12 weeks		Normalization of neurodevelopment
Bavle et al. [12]	2 months/female	Disseminated: chiasm/b/l optic nerves/thalami/cerebellum	BRAF-V600E	Vincristine/carboplatin x 18 months	Selumetinib x 8 weeks	Partial radiological response	Vesicles/keratosis pilaris/fever
						Improvement in oral intake
				Vinblastine x 8 weeks	Dabrafenib	Decreased Seizures
Howden et al. (Current study)	2 years/female	Hypothalamic/chiasmatic	BRAF-V600E	Vincristine/carboplatin x 6 weeks	Dabrafenib	Profound/sustained radiological response	Nil
						Improvement in vision
						Normalization of neurodevelopment